Topic

Surrozen

A collection of 2 issues

Surrozen Stock Upgraded After Promising Phase 1b Results

Surrozen's stock receives a 'Buy' upgrade due to positive results from Phase 1b trials, boosting investor confidence in the biotech company's future prospects.

Guggenheim Upgrades Surrozen on Promising Liver Disease Data

Guggenheim upgrades Surrozen (SRZN) following promising Phase 1b trial results for its lead liver disease asset. Explore implications for SRZN stock.